Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Julia, Foster"'
Autor:
Joan How, Siyang Ren, Jennifer Lombardi‐Story, Meghan Bergeron, Julia Foster, Phillip C. Amrein, Andrew M. Brunner, Amir T. Fathi, Hanno Hock, Anna Khachatryan, Hiroto Kikuchi, Mei Rosa Ng, Jenna Moran, Rupa Narayan, Donna Neuberg, Aura Ramos, Tina Som, Meghan Vartanian, Yi‐Bin Chen, Dan G. Duda, Gabriela S. Hobbs
Publikováno v:
eJHaem, Vol 3, Iss 2, Pp 434-442 (2022)
Abstract We conducted a single‐center, open‐label, dose escalation, and expansion phase I trial of the antiangiogenic multikinase inhibitor regorafenib in patients with advanced myeloid neoplasms. We enrolled 16 patients with relapsed/refractory
Externí odkaz:
https://doaj.org/article/b768134a01424428b03dc52b7afb2c56
Autor:
Valentina Nardi, Nora Ku, Matthew J. Frigault, Adrian M. Dubuc, Harrison Kwei Tsai, Philip C. Amrein, Gabriela S. Hobbs, Andrew M. Brunner, Rupa Narayan, Meghan E. Burke, Julia Foster, Paola Dal Cin, Marcela V. Maus, Amir T. Fathi, Hanno Hock
Publikováno v:
Blood Advances, Vol 4, Iss 1, Pp 106-111 (2020)
Abstract: Philadelphia chromosome (Ph)–like acute lymphoblastic leukemia (ALL) is a subtype of Ph-negative ALL that molecularly resembles Ph-positive ALL. It shares the adverse prognosis of Ph-positive ALL, but lacks the BCR-ABL1 fusion oncogene. I
Externí odkaz:
https://doaj.org/article/7fc7238856444e36b2853dd5b133bf4f
Autor:
Valentina Nardi, Steven L McAfee, Paola Dal Cin, Harrison K Tsai, Philip C Amrein, Gabriela S Hobbs, Andrew M Brunner, Rupa Narayan, Julia Foster, Amir T Fathi, Hanno Hock
Publikováno v:
The Oncologist. 27:82-86
BCR-ABL1 kinase inhibitors have improved the prognosis of Philadelphia-chromosome-positive (Ph+)-acute lymphoblastic leukemia (ALL). Ph-like (or BCR-ABL1-like) ALL does not express BCR-ABL1 but commonly harbors other genomic alterations of signaling
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04d6069b5329e0f6f92acd2747e07497
https://doi.org/10.1093/oncolo/oyab052
https://doi.org/10.1093/oncolo/oyab052
Autor:
Philip, Amrein, Karen, Ballen, Kristen, Stevenson, Andrew, Brunner, Gabriela, Hobbs, Hanno, Hock, Steven, McAfee, Jenna, Moran, Meghan, Bergeron, Julia, Foster, Christina, Bertoli, Kristin, McGreggor, Molly, Macrea, Meghan, Burke, Tanya, Behnam, Tina, Som, Aura, Ramos, Megan, Vartanian, Jennifer, Lombardi Story, Christine, Connolly, Traci, Blonquist, Donna, Neuberg, Amir, Fathi
Publikováno v:
Leukemia & Lymphoma. 63:1428-1435
We sought to assess the safety of adding ixazomib, an oral proteasome inhibitor, to a multi-agent treatment regimen for older adults with acute lymphoblastic leukemia (ALL). Patients 51 to 75 years of age with newly diagnosed ALL were screened. Induc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d04e1e4dcbaea28e23d903a5a5446652
https://doi.org/10.1080/10428194.2021.2018582
https://doi.org/10.1080/10428194.2021.2018582
Autor:
Erin Moshier, Molly Macrae, Martha Wadleigh, Camelia Iancu-Rubin, Kathryn Johnson, Michal Bar-Natan, Nina Bhardwaj, Gabriela S. Hobbs, Tina T. Som, Cansu Cimen Bozkus, Mikeaela Dougherty, John Mascarenhas, Lonette Sandy, Hetal D. Marble, Siraj M. El Jamal, Nicole Zubizarreta, Richard Stone, Mohamad E. Salama, Julia Foster
Publikováno v:
Blood Advances. 5:5086-5097
Myelofibrosis (MF) is a clonal stem cell neoplasm characterized by abnormal JAK-STAT signaling, chronic inflammation, cytopenias, and risk of transformation to acute leukemia. Despite improvements in the therapeutic options for patients with MF, allo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64d1a717b4063687b9a283d148f06048
https://doi.org/10.1182/bloodadvances.2021005491
https://doi.org/10.1182/bloodadvances.2021005491
Autor:
Amir T. Fathi, Seth A. Wander, Traci M. Blonquist, Andrew M. Brunner, Philip C. Amrein, Jeffrey Supko, Nicole M. Hermance, Amity L. Manning, Hossein Sadrzadeh, Karen K. Ballen, Eyal C. Attar, Timothy A. Graubert, Gabriela Hobbs, Christelle Joseph, Ashley M. Perry, Meghan Burke, Regina Silver, Julia Foster, Meghan Bergeron, Aura Y. Ramos, Tina T. Som, Kaitlyn M. Fishman, Kristin L. McGregor, Christine Connolly, Donna S. Neuberg, Yi-Bin Chen
Publikováno v:
Haematologica, Vol 102, Iss 4 (2017)
Aberrant expression of aurora kinase A is implicated in the genesis of various neoplasms, including acute myeloid leukemia. Alisertib, an aurora A kinase inhibitor, has demonstrated efficacy as monotherapy in trials of myeloid malignancy, and this ef
Externí odkaz:
https://doaj.org/article/3505135afba4471f95cb8a4b2bb74035
Autor:
Kevin C. Miller, Jennifer Lombardi Story, Julia Foster, Jenna A. Moran, Amir T. Fathi, Gabriela S. Hobbs
Publikováno v:
Blood. 140:12295-12296
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::15938bdd24096ff05d1b55462012ebdb
https://doi.org/10.1182/blood-2022-170986
https://doi.org/10.1182/blood-2022-170986
Autor:
Jenna A. Moran, Philip C. Amrein, Chrisa Hunnewell, Amir T. Fathi, Meghan Bergeron, Timothy A. Graubert, Valentina Nardi, Julia Foster, Andrew M. Brunner, Keagan S Casey, Maristela L. Onozato, Vinayak Venkataraman, Steven L. McAfee, Matthew J. Frigault, Gabriela S. Hobbs, Hanno Hock, Paola Dal Cin
Publikováno v:
Leukemia. 34:3050-3054
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c1ebf1302017ea4b10911e77162cc3c7
https://doi.org/10.1038/s41375-020-0983-x
https://doi.org/10.1038/s41375-020-0983-x
Autor:
Tina T. Som, Gabriela S. Hobbs, Meghan Burke, Yi-Bin Chen, Kristin McGregor, Steven L. McAfee, Robb S Friedman, Karim A. Benhadji, Paola Dal Cin, Meghan Vartanian, Monica Kasbekar, Julia Foster, Rupa Narayan, Molly Macrae, Aura Y. Ramos, Valentina Nardi, Andrew M. Brunner, Amir T. Fathi, Christine Connolly
Publikováno v:
Blood Adv
Key Points A novel PCM1-FGFR1 gene rearrangement was identified in a patient with a myeloid neoplasm with eosinophilia. Futibatinib, an oral selective small molecule inhibitor of FGFR1-4, resulted in a durable complete hematologic and cytogenetic rem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8e25d72af4a7081f705d17df0a50ec5
https://doi.org/10.1182/bloodadvances.2020002308
https://doi.org/10.1182/bloodadvances.2020002308
Autor:
Rupa Narayan, Robert P. Hasserjian, Margaret C. Wey, Tanya T. Behnan, Meghan Bergeron, Jessica Rae, Mason L. Mann, Ashkan Emadi, Christina Bertoli, Eyal C. Attar, Traci M. Blonquist, Christopher Lescinskas, Jenna A. Moran, Yi-Bin Chen, Steven L. McAfee, Vu H. Duong, Patricia Lesho, Timothy A. Graubert, Jennifer Lombardi Story, Andrew M. Brunner, Meghan Burke, Megan K. Vartanian, Gabriela S. Hobbs, Tina T. Som, Donna Neuberg, Hanno Hock, Molly Macrae, Julia Foster, Kristin McGregor, Philip C. Amrein, Amir T. Fathi, Karen K. Ballen, Frederic I. Preffer, Aura Y. Ramos, Christine Connolly
Publikováno v:
Cancer. 126:1264-1273
Background Outcomes for patients with relapsed/refractory acute myeloid leukemia (R/R AML) remain poor. Novel therapies specifically targeting AML are of high interest. Brentuximab vedotin (BV) is an antibody-drug conjugate that is specific for human
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::411429856bce3fe963798cabff48aa70
https://doi.org/10.1002/cncr.32657
https://doi.org/10.1002/cncr.32657